SCHEMBL3328080

SCHEMBL3328080

C[C@H](C=O)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3330387 1.00
SCHEMBL1644130 1.00
2-Oxoisohexanoate SCHEMBL7185279 0.85 CA2 (0.37)
Valine SCHEMBL22070191 0.83 SLC7A5 (0.58)
SCHEMBL13011645 0.80 CACNA2D1 (0.38)
SCHEMBL6439560 0.80 SLC22A6 (0.43)
SCHEMBL6439563 0.80 SLC22A6 (0.43)
SCHEMBL7531470 0.79 CACNA2D1 (0.36)
SCHEMBL28054325 0.79 SLC22A6 (0.50)
SCHEMBL10406061 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029715-B2 Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof UNIVERSITY OF DEBRECEN (HU) 2024-07-09 US disclosed
CN-108570438-B Method for producing α -ketoisovalerate by improving Klebsiella pneumoniae and modified bacteria 中国科学院上海高等研究院 2020-06-30 CN disclosed
US-20190054056-A1 PRECURSOR COMPOUNDS FOR PROVIDING RETINOIDS OF THE VATAMIN A5 PATHWAY AND USES THEREOF UNIVERSITY OF DEBRECEN (HU) 2019-02-21 US disclosed
US-9352010-B2 Treatment of HIV-1 infection and AIDS THE J. DAVID GLADSTONE INSTITUTES (US) 2016-05-31 US disclosed
US-20160008420-A1 Treatment Of HIV-1 Infection And AIDS THE J. DAVID GLADSTONE INSTITUTES 2016-01-14 US disclosed
EP-2399915-B1 Process and intermediates for the preparation of aspartic acetal caspase inhibitors VERTEX PHARMA (US) 2014-12-17 EP disclosed
US-8889660-B2 Methods for treating obesity or an obesity related condition CASE WESTERN RESERVE UNIVERSITY (US) 2014-11-18 US disclosed
US-20130072555-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES CASE WESTERN RESERVE UNIVERSITY (US) 2013-03-21 US disclosed
US-8338394-B2 Methods for treating metabolic diseases CASE WESTERN RESERVE UNIVERSITY (US) 2012-12-25 US disclosed
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
EP-2295442-A2 Inhibitors of interleukin-1beta converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-16 EP disclosed
EP-2270004-A1 Caspase inhibitors and uses thereof Vertex Pharmceuticals Incorporated (US) 2011-01-05 EP disclosed
US-7790713-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-09-07 US disclosed
US-7790713-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-09-07 US disclosed
US-20100135977-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-06-03 US disclosed
EP-2123665-A2 Inhibitors of interleukin-1Beta converting enzyme Vertex Pharmaceuticals Incorporated (US) 2009-11-25 EP disclosed
EP-2083014-A2 Inhibitors of interleukin-1ß converting enzyme Vertex Pharmceuticals Incorporated (US) 2009-07-29 EP disclosed
US-7473671-B2 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2009-01-06 US disclosed
WO-2008063768-A2 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES CASE WESTERN RESERVE UNIVERSITY (US) 2008-05-29 WO disclosed
WO-2005085236-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-09-15 WO disclosed